Long-term effect on body composition and metabolic parameters after treatment with recombinant human growth hormone (r-hGH) in HIV-1 infected patients with lipodystrophy

Scandinavian Journal of Infectious Diseases

Volumn 40, Issue 1, 2008, Pages 36-39

  Bickel, Markus ^a   Zangos, Stephan ^b   Lutz, Thomas ^c   Eisen, Johannes ^b   Knecht, Gabi ^c   Goebel, Frank ^d   Crespi, Catherine ^e   Jacobi, Volkmar ^b   Staszewski, Schlomo ^a   Klauke, Stephan ^c  

^a HIV Medical Treatment and Research Unit   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c Private Practice ^*  (Germany)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; PROTEINASE INHIBITOR; RECOMBINANT GROWTH HORMONE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; BODY COMPOSITION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INTRAABDOMINAL FAT; MAINTENANCE DRUG DOSE; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS FAT;

ADOLESCENT; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BODY FAT DISTRIBUTION; FEMALE; HIV INFECTIONS; HIV-1; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMAN GROWTH HORMONE; HUMANS; INTRA-ABDOMINAL FAT; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES;

EID: 37749003809     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.1080/00365540701487955     Document Type: Article

References (15)

1. Carr, A., Samaras, K., Burton, S., Law, M., Freund, J. and Chisholm, DJ (1998) A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS, 12, p. F51.
2. HIV Lipodystrophy Case Definition Study Group (2003) An objective case definition of lipodystrophy in HIV-infected adults: A case-control study. Lancet, 361, pp. 726-735.
3. Kotler, DP, Rosenbaum, K., Wang, J. and Pierson, RN (1999) Studies of body composition and fat distribution in HIV-infected and control subjects. J Acquir Immune Defic Syndr Hum Retrovirol, 20, pp. 228-237.
4. Lamarche, B. (1998) Abdominal obesity and its metabolic complications: implications for the risk of ischaemic heart disease. Coron Artery Dis, 9, pp. 473-481.
5. Esposito, K., Nicoletti, G. and Giugliano, D. (2002) Obesity, cytokines and endothelial dysfunction: A link for raised cardiovascular risk associated with visceral obesity. J Endocrinol Invest, 25, pp. 646-649.
6. Fujimoto, WY, Bergstrom, RW, Boyko, EJ, Chen, KW, Leonetti, DL and Newell-Morris, L. (1999) Visceral adiposity and incident coronary heart disease in Japanese-American men. The 10-y follow-up results of the Seattle Japanese-American Community Diabetes Study. Diabetes Care, 22, pp. 1808-1812.
7. Hadigan, C., Meigs, JB, Corcoran, C., Rietschel, P., Piecuch, S. and Basgoz, N. (2001) Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis, 32, pp. 130-139.
8. Grinspoon, S. and Carr, A. (2005) Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med, 352, pp. 48-62.
9. Lo, JC, Mulligan, K., Noor, MA, Schwarz, JM, Halvorsen, RA and Grunfeld, C. (2001) The effects of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation. J Clin Endocrinol Metab, 86, pp. 3480-3487.
10. Kotler, DP, Muurahainen, N., Grunfeld, C., Wanke, C., Thompson, M., Saag, M., Kotler, DP, Muurahainen, N., Grunfeld, C., Wanke, C., Thompson, M. and Saag, M. (2004) Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidaemia in HIV-infected patients. J Acquir Immune Defic Syndr, 35, pp. 239-252.
11. Wanke, C., Gerrior, J., Kantaros, J., Coakley, E. and Albrecht, M. (1999) Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV. AIDS, 13, pp. 2099-2103.
12. Engelson, ES, Glesby, MJ, Mendez, D., Albu, JB, Wang, J. and Heymsfield, SB (2002) Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection. J Acquir Immune Defic Syndr, 30, pp. 379-391.
13. He, Q., Engelson, ES, Albu, JB, Heymsfield, SB and Kotler, DP (2003) Preferential loss of omental-mesenteric fat during growth homone therapy of HIV-associated lipodystrophy. J Appl Physiol, 94, pp. 2051-2057.
14. Koutkia, P., Canavan, B., Breu, J., Torriani, M., Kissko, J. and Grinspoon, S. (2004) Growth hormone-releasing hormone in HIV-infected men with lipodystrophy. JAMA, 292, pp. 210-218.
15. Bickel, M., Zangos, S., Jacobi, V., Lutz, T., Knecht, G. and Goebel, F. (2006) A randomized, open-label study to compare the effects of 2 different doses of recombinant human growth hormone on fat reduction and fasting metabolic parameters in HIV-1-infected patients with lipodystrophy. HIV Med, 7, pp. 397-403.